PI
RGLS

PEAK6 Investments’s Regulus Therapeutics RGLS Stock Holding History

PEAK6 Investments’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$94.2K Hold
60,000
– – ﹤0.01% 2998
2024
Q2 		$107K Buy
+60,000
New +$139K ﹤0.01% 3008

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PEAK6 Investments's RGLS Position: Q3 2024 in Review

PEAK6 Investments held its Regulus Therapeutics (RGLS) position steady in Q3 2024 at 60,000 shares worth $94.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2998.

PEAK6 Investments first reported a position in RGLS in Q2 2024 and has held it in 2 quarters since. The position peaked at $107K in Q2 2024. 70 funds tracked by Wall St. Rank hold RGLS as of Q3 2024.

  • PEAK6 Investments held 60,000 shares of Regulus Therapeutics worth $94.2K as of Q3 2024.
  • PEAK6 Investments left its Regulus Therapeutics share count unchanged in Q3 2024.
  • Regulus Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2998 holding.
  • PEAK6 Investments first reported a position in Regulus Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • PEAK6 Investments's Regulus Therapeutics position peaked at $107K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.